Farthing C, Khanlou H, Yeh V; IAS Conference on HIV Pathogenesis and Treatment (2nd : 2003 : Paris, France).
Antivir Ther. 2003; 8 (Suppl.1): abstract no. 43.
AIDS Healthcare Foundation, Los Angeles, CA, USA
Introduction: Previous investigational data using abacavir (ABC), lamuvidine (3TC) and zidovudine has suggested the possibility of triple nucleoside analogue reverse transcriptase inhibitors (NRTI) therapy as an option in the treatment of HIV infection. We performed a pilot study to assess the potency of once-daily ABC+3TC+tenofovir (TDF) in the treatment of HIV-infected naive patients. CD4 and HIV-VL were followed monthly. Patients were considered to be non-responder/failing if there was no reduction in VL by 32 log10 by week 8 and/or a rebound in VL after initial suppression. Resistance testing was then obtained. RESULTS: Twenty patients (pts) naive to ARVs (3 women and 17 men) were enrolled, of which 3 withdrew from study: 1 with allergy to ABC, 1 discharged due to non-adherence and 1 did not return for follow-up. Mean VL and CD4 count at baseline were 82 381 copies/ml [range: 7650-213486] and 273 cells/mm3 [range: 59-598]. Nine pts had VL>100000 at baseline. After therapy, the mean VL drop at week 4 and 8 were respectively 14898 and 8 219. From 17 patients, 9 [52%] had VL rebound: 1 at week 4, 6 at week 8 and 2 at week 16. The pts were adherent >95% by pill count. Genotypic analysis showed M184V mutation in 2 pts, M184V+K65R in 1 pt and 6 other samples are pending. Study was prematurely interrupted because of these results. CONCLUSION: Although preliminary, these results raise the concern about potency and efficacy of this regimen administered once-daily in HIV treatment naive pts, particularly those with initial VL >100000.
Publication Types:
Keywords:
- AIDS Vaccines
- Acquired Immunodeficiency Syndrome
- Adenine
- Antiretroviral Therapy, Highly Active
- CD4 Lymphocyte Count
- Dideoxynucleosides
- Drug Therapy, Combination
- Female
- HIV Infections
- HIV Seropositivity
- Humans
- Lamivudine
- Male
- Phosphonic Acids
- Pilot Projects
- Reverse Transcriptase Inhibitors
- Zidovudine
- abacavir
- drug therapy
- tenofovir
- therapy
Other ID:
UI: 102262374
From Meeting Abstracts